Education
About Us
Working with TipRanks
Follow Us
Dexcom (DXCM)
:DXCM
DXCM Stock Chart & Stats
$64.85
$0.53(0.67%)
At close: 4:00 PM EST
$64.85
$0.53(0.67%)
Day’s Range― - ―
52-Week Range$54.11 - $93.25
Previous CloseN/A
Volume488.69K
Average Volume (3M)7.13M
Market Cap
$25.14B
Enterprise Value$26.67B
Total Cash (Recent Filing)$3.32B
Total Debt (Recent Filing)$2.52B
Price to Earnings (P/E)35.9
Beta1.11
Next Earnings
Feb 05, 2026EPS Estimate
0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.61
Shares Outstanding390,016,270
10 Day Avg. Volume4,750,382
30 Day Avg. Volume7,131,860
Financial Highlights & Ratios
PEG Ratio39.32
Price to Book (P/B)14.97
Price to Sales (P/S)7.80
P/FCF Ratio49.89
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue5.91
Enterprise Value/Gross Profit10.01
Enterprise Value/Ebitda21.90
Forecast
1Y Price Target
$86.35Price Target Upside33.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
EPS Forecast (FY)2.06
Revenue Forecast (FY)$4.65B
Bulls Say, Bears Say
Bulls Say
Growth ExpectationsAnalysts maintain a Buy rating for Dexcom, anticipating double-digit growth and near-term catalysts.
Medicare Payment AlignmentThe OIG report shows that Class 2 supplies are priced fairly in line with Medicare expectations, minimizing potential risks from competitive bidding.
Revenue And Market PerformanceDexcom reported Q3 revenue of $1.209B, a $30M beat on consensus estimates, with strong new patient starts.
Bears Say
Guidance And MarginsThe guide was disappointing with 2025 revenue lifted to reflect Q3 results but GM and adjusted EBITDA guidance lowered as costs related to quality issues continue to impact the P&L.
Investor SentimentInvestor sentiment on Dexcom has been negative over the past several months due to concerns about high Street estimates for 2026 and noise around accuracy issues impacting new patient starts.
Product Quality And Competitive ThreatsProduct quality issues and competitive threats will continue to disrupt DXCM’s share gain opportunity.
Dexcom News
DXCM FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest stock price was $54.11 and its highest was $93.25 in the past 12 months.
What is Dexcom’s market cap?
Dexcom’s market cap is $25.14B.
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is Feb 05, 2026 which is in 63 days.
How were Dexcom’s earnings last quarter?
Dexcom released its earnings results on Oct 30, 2025. The company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.576 by $0.034.
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is 0.65.
How many shares outstanding does Dexcom have?
Dexcom has 390,016,270 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Dexcom reported an EPS of $0.61 in its last earnings report, beating expectations of $0.576. Following the earnings report the stock price went down -14.633%.
Which hedge fund is a major shareholder of Dexcom?
Currently, no hedge funds are holding shares in DXCM
Dexcom Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$86.35 (33.15% Upside)
$86.35 (33.15% Upside)
Blogger Sentiment
Bullish
DXCM Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days >0.1%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-19.84%
12-Months-Change
Fundamentals
Return on Equity
30.63%
Trailing 12-Months
Asset Growth
18.04%
Trailing 12-Months
Company Description
Dexcom
Dexcom, Inc. is a medical device company that specializes in continuous glucose monitoring (CGM) systems for people with diabetes. Founded in 1999 and headquartered in San Diego, California, Dexcom develops innovative technologies to help patients manage their blood glucose levels more effectively. Its core products include the Dexcom G6 and G7 CGM systems, which provide real-time glucose data and trends to users, enhancing their ability to make informed decisions about their diabetes management. The company operates primarily in the healthcare sector, focusing on diabetes care and management solutions.
DXCM Company Deck
DXCM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
DexCom's earnings call highlighted robust revenue growth and strategic product expansions, particularly in type 2 diabetes CGM coverage, and noted the introduction of innovative products like DexCom Smart Basal. However, challenges in gross margin management and quality issues with the G7 sensor deployment were noted. The sentiment is buoyed by positive financial performance and strategic advancements, despite some operational challenges.View all DXCM earnings summariesDXCM Revenue Breakdown
71.65% U.S.
28.35% Outside of the U.S.
DXCM Stock 12 Month Forecast
Average Price Target
$86.35
▲(33.15% Upside)
Technical Analysis
Ownership Overview
0.48% Insiders
28.18% Mutual Funds
18.20% Other Institutional Investors
22.36% Public Companies and Individual Investors